ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / LGND
RYTM (38) BLTE (36) MANE (55) IONS (26) ⌘ Pro Terminal →

Ligand Pharmaceuticals Incorporated (LGND) — RQD Stock Rating Cockpit

$307.02 -4.87% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $303.75

Ligand Pharmaceuticals Incorporated (LGND) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $6.43B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LGND Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LGND stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $307.02 (-4.87% 1D, market cap $6.43B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 18/20, SEC Balance-Sheet Forensics 15/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, LGND ranks #147 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LGND compare to RYTM and BLTE in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LGND carries a Roarable C (62/100 RQD), trailing P/E of 50.8x, gross margin of —, and ROIC of 3.0%. By comparison, RYTM (Rhythm Pharmaceuticals Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -29.6%, cap $6.37B) and BLTE (Belite Bio Inc) posts a D- grade (36/100 RQD, P/E N/A, ROIC -15.9%, cap $6.23B). Among the 5-stock peer group, LGND leads on earnings multiple (50.8x) while LGND leads on capital efficiency (3.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LGND?
▼

Per LGND's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000886163), Ligand Pharmaceuticals Incorporated generated $268.1M in revenue (+60.4% YoY), $124.5M in net income, and $48.9M in free cash flow against $1.56B in total assets and $244.5M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $303.73 (-1.07%)🧬 Disciplined Float (+0.80% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 18.2% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY • 54.3% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C
025507510062
2-of-3 Quant Analysts Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D+ · Rk B-
Cash (7)Whales (18)SEC (15)Macro (13)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE+1.8% Base Target
$369 Bull$313 Base$244 Bear
📬 FREE LGND RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LGND)Realized 20D OHLCV Swing Band: ±6.9%
Deterministic 5-Pillar Attribution (62/100 Composite)
🔍 WHY LGND SCORES 62/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+18/20 pts (29% of score)

20D Institutional Volume Accumulation (±6.9% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+15/20 pts (24% of score)

Altman Z-Score 8.40 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▼ #1 Drag / Risk Factor: Cash Engine Quality7/20 pts (-13 pt drag)

Capital intensity & 15.3% operating margin leave 13 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
54
Grade C-$294.99+6.7% Next Q
Q2 (-2Q)
57
Grade C$314.78+1.3% Next Q
Q3 (-1Q)
59
Grade C$318.78-3.7% Next Q
Current
62
Grade C$307.02+0.7% Hist 90D α
Trajectory: C- (54) → C (62)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the LGND Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 62/100 (C) score, LGND faces multiple-compression risk if 50.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Priced at 51x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($298.58) or 200D SMA ($254.51) invalidates the momentum regime and cuts Target Base ($312.55) toward Bear Floor ($243.79).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LGND• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LGND Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 62%NO 38%Trade / Inspect Odds →
RSI-14 MOMENTUMBULLISH MOMENTUM
61.930 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
8.40>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
8 / 99-Pt Accounting
52-WEEK LASER RANGE87% OF RANGE
L: $176$307.02H: $327
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20
2. Big Money & Insiders● NEUTRAL
Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: C+RQD 27 / 40
3. Hidden Risks & Market Weather● ALL CLEAR
SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: B-RQD 28 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

2-of-3 Quant Analysts Bullish on LGND

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (35)

3.0% ROIC with 42.0% gross margin and 0.77% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (75)

Altman-Z 8.40 and Piotroski 8/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BULLISH (67)

27/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like LGND
  • ✓Big institutional funds and options desks are actively positioning on the bullish side.
  • ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Priced at 51x earnings—high expectations leave less room for a lukewarm quarter.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (LGND Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
LGND // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +34.45%🛡️ HOLDING TREND SUPPORT
2026-11-03O $317.3H $322.8L $307.0C $307.0VOL 344.4K
RES: $325.3SUP: $296.4SMA50: $298.6SMA200: $254.5
$336.4$296.0$255.7$215.4$175.0RES $325.3SUP $296.4$307.02026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LGND Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LGND Butterfly Map → + Track LGND →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
36.8%/yr Implied 5Y Growth

vs. +60.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on LGND today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LGND. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LGND today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LGND)

Health Care Rank #147 of 1015 ⚔️ RYTM vs LGND Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LGND vs. RYTM, BLTE, MANE, IONS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Ligand Pharmaceuticals Incorporated (LGND) ranks #147 by composite RQD confidence (62/100, grade C) and #138 by equity capitalization ($6.43B). Within this direct 5-issuer industry benchmark cohort, LGND leads on earnings valuation at 50.8x trailing P/E, while LGND leads on capital efficiency and profitability with 3.0% ROIC and — gross margin. LGND currently leads its immediate peer cohort in composite quantitative strength at 62/100 (C).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
LGND ACTIVE
Ligand Pharmaceuticals Incorporated
C 62/100 50.8x — 3.0% -4.87% $6.43B Benchmark Subject
RYTM
Rhythm Pharmaceuticals Inc.
D- 38/100 — 89.7% -29.6% +0.94% $6.37B /rytm-vs-lgnd →
BLTE
Belite Bio Inc
D- 36/100 — — -15.9% -0.69% $6.23B /blte-vs-lgnd →
MANE
Veradermics Incorporated
D+ 55/100 — — -11.9% -7.27% $5.84B /mane-vs-lgnd →
IONS
Ionis Pharmaceuticals Inc.
E 26/100 — 96.0% -20.9% -5.24% $7.23B /ions-vs-lgnd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000886163 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Ligand Pharmaceuticals Incorporated (LGND) reported GAAP revenue of $268.1M (+60.4% vs. FY2024 revenue of $167.1M , and +104.2% cumulative change since FY2023) , GAAP net income of $124.5M, operating cash flow of $49.4M, and free cash flow of $48.9M (-48.6% YoY). On the balance sheet, LGND closed FY2025 with $1.56B in total assets against $244.5M in total debt (Altman Z-Score: 8.40, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $268.1M $124.5M $49.4M $48.9M $1.56B $244.5M
FY2024 (FY) 2024-12-31 $167.1M -$4.0M $97.0M $95.2M $941.8M $50.1M
FY2023 (FY) 2023-12-31 $131.3M $52.2M $49.6M $43.7M $3.48B $814.2M

3. LGND Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LGND stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $307.02 (-4.87% 1D, market cap $6.43B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 18/20, SEC Balance-Sheet Forensics 15/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, LGND ranks #147 in composite RQD confidence.

How does LGND compare to RYTM and BLTE in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LGND carries a Roarable C (62/100 RQD), trailing P/E of 50.8x, gross margin of —, and ROIC of 3.0%. By comparison, RYTM (Rhythm Pharmaceuticals Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -29.6%, cap $6.37B) and BLTE (Belite Bio Inc) posts a D- grade (36/100 RQD, P/E N/A, ROIC -15.9%, cap $6.23B). Among the 5-stock peer group, LGND leads on earnings multiple (50.8x) while LGND leads on capital efficiency (3.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LGND?

Per LGND's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000886163), Ligand Pharmaceuticals Incorporated generated $268.1M in revenue (+60.4% YoY), $124.5M in net income, and $48.9M in free cash flow against $1.56B in total assets and $244.5M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LGND trading relative to its 50-day, 200-day, and 52-week technical levels?

LGND last traded at $307.02 (-4.87% on volume of 265,507 shares), positioning the stock +2.83% above its 50-day simple moving average ($298.58) and +20.63% above its 200-day simple moving average ($254.51). Across its 52-week range of $175.89 to $326.63, LGND sits at the 87.0% percentile with a 14-day RSI of 61.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.9% ($285.84 to $328.20).

Direct Sub-Reports: LGND RQD Cockpit LGND 12M Forecast LGND Earnings & Move LGND Dividends & DRIP LGND Insiders & 13F LGND Whale Options LGND Profit Sankey LGND News & Why
ROARABLE RATING BRIEF • RQD 62/100 (C) ✓ SEC XBRL & RQD VERIFIED

LGND — Ligand Pharmaceuticals Incorporated: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Ligand Pharmaceuticals Incorporated (LGND) earns a live Roarable RQD composite score of 62/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $307.02 (-4.87% 1D, market capitalization $6.43B).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of 3.0%, gross margin of —, operating margin of 15.3%, and free cash flow yield of 0.77%.
  • Whale 13F & Options Flow (18/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (13/20) + Forensic Balance Sheet (15/20): Incorporates a 1.07x equity beta, Altman Z-Score of 8.40, Piotroski F-Score of 8/9, and Debt/Equity of 0.22x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Ligand Pharmaceuticals Incorporated is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry..3B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Ligand Pharmaceuticals Incorporated (LGND) reported $268.1M in annual revenue (up from $167.1M in FY2024, +60.4% YoY) and $124.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($131.3M revenue, $52.2M net income) through FY2025, LGND scaled operating cash flow to $49.4M and free cash flow to $48.9M, backed by $1.56B in total assets against $244.5M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C • RQD 62/100): Big institutional funds and options desks are actively positioning on the bullish side. Clean SEC annual filing review with no major hidden accounting time-bombs. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 18/20, sustained execution supports upside toward the upper end of the $175.89 – $326.63 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh 50.8x trailing P/E and 95.0x EV/EBITDA against 15.3% operating margins and a 1.07x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The supply chain is NONE, with empty butterfly links and empty proprietary signals. — for upstream or downstream dependencies, sector correlations beyond the beta reading, or second-order bottlenecks. A prospective investor should note that the absence of mapped links means this analysis cannot identify ripple effects from the data provided.

  • Key Question #1: Can LGND sustain or expand its 15.3% operating margin and 3.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $268.1M and free cash flow of $48.9M, how will capital allocation balance growth reinvestment against $244.5M in total debt?
  • Key Question #3: How sensitive is LGND's 42.7x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.07x)?

LGND Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Ligand Pharmaceuticals Incorporated (LGND) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LGND Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LGND Bull vs. Bear Conversation Board — What's Your Call at $307.02?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LGND 🐻 33% BEARISH CONVICTION
1. Pick Your Side on LGND:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $419.57 (+30.0%)
📌 Pinned Debate

Institutional accumulation and options positioning score 17 of 20 in the RQD rating, the strongest pillar, alongside an Altman Z-Score

Here is why I am bullish on LGND here at $322.75: Institutional accumulation and options positioning score 17 of 20 in the RQD rating, the strongest pillar, alongside an Altman Z-Score of 8.4 and Piotroski F-Score of 8 of 9.. Compare LGND's 15.3% operating margin and 3.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $306.61 are getting bought.

RetailWhale_TX 🐂 BULL

@BearTrap_Alert Shorting a 18/20 institutional whale-flow stock at $322.75 is dangerous when funds are rotating into Health Care.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $267.88 (-17.0%)
Spot @ $322.75

Trading at a P/E (TTM) of 50.8 and EV/EBITDA of 95 with a 0.77% FCF yield and 3% ROIC, the stock's valuation is not supported by curren

Trading at a P/E (TTM) of 50.8 and EV/EBITDA of 95 with a 0.77% FCF yield and 3% ROIC, the stock's valuation is not supported by current cash-generation returns.. Look at the math on LGND: paying 50.8x trailing P/E for 3.0% ROIC and 15.3% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $284.02 before getting long.

LIVE TAPE